Bioasis Technologies Inc.

OTCPK:BIOA.F Stock Report

Market Cap: US$15.9k

Bioasis Technologies Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Deborah Rathjen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.8yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure6.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Deborah Rathjen's remuneration changed compared to Bioasis Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Nov 30 2022n/an/a

-CA$3m

Aug 31 2022n/an/a

-CA$3m

May 31 2022n/an/a

-CA$3m

Feb 28 2022CA$307kCA$209k

-CA$3m

Nov 30 2021n/an/a

-CA$3m

Aug 31 2021n/an/a

-CA$1m

May 31 2021n/an/a

CA$1m

Feb 28 2021CA$268kCA$190k

CA$698k

Nov 30 2020n/an/a

CA$754k

Aug 31 2020n/an/a

-CA$494k

May 31 2020n/an/a

-CA$4m

Feb 29 2020CA$282kCA$192k

-CA$4m

Nov 30 2019n/an/a

-CA$4m

Aug 31 2019n/an/a

-CA$4m

May 31 2019n/an/a

-CA$3m

Feb 28 2019CA$105kn/a

-CA$3m

Nov 30 2018n/an/a

-CA$5m

Aug 31 2018n/an/a

-CA$6m

May 31 2018n/an/a

-CA$6m

Feb 28 2018CA$283kn/a

-CA$5m

Compensation vs Market: Insufficient data to establish whether Deborah's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Deborah's compensation with company performance.

CEO

Deborah Rathjen (66 yo)

5.8yrs

Tenure

CA$306,657

Compensation

Dr. Deborah Ann Rathjen, B.Sc. (Hons.), Ph D., M.A.I.C.D., FTSE, Q.C. has been the President and Chief Executive Officer of Bioasis Technologies Inc. since March 11, 2019. Dr. Rathjen served as the Chief E...

Board Members

NamePositionTenureCompensationOwnership
Jeffrey Cummings
Member of Scientific Advisory Board7.3yrsno datano data
John Wikswo
Member of Scientific Advisory Board7.3yrsno datano data
May Orfali
Member of Medical Oncology Advisory Boardno datano datano data
John Krystal
Chairman of Scientific Advisory Board7.3yrsno datano data
Hope Rugo
Member of Medical Oncology Advisory Board5.1yrsno datano data
John Hoppin
Member of Scientific Advisory Board6.6yrsno datano data
John de Groot
Member of Medical Oncology Advisory Board5.1yrsno datano data
Sue O'Connor
Member of Scientific Advisory board6.6yrsno datano data
Javier Cortés
Member of Medical Oncology Advisory Board5.1yrsno datano data

6.6yrs

Average Tenure

Experienced Board: BIOA.F's board of directors are considered experienced (6.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 22:08
End of Day Share Price 2025/01/03 00:00
Earnings2022/11/30
Annual Earnings2022/02/28

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bioasis Technologies Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathaniel CallowayEdison Investment Research
William GregozeskiGreenridge Global LLC
John VandermostenZacks Small-Cap Research